Health Canada approves Novartis' KISQALI® for HR+/HER2- early breast cancer patients at high risk of recurrence Français
Health Canada approval is based on the pivotal Phase III NATALEE trial data, which demonstrated a clinically meaningful invasive disease-free survival (iDFS) benefit for KISQALI ® plus adjuvant aromatase inhibitor (AI) in patients with stage II or III HR+/HER2- eBC. 2
KISQALI is currently the only CDK4/6 inhibitor that has demonstrated statistically significant improvement in overall survival in three Phase III trials in advanced breast cancer. 3,4,5
MONTREAL, June 18, 2025 /CNW/ - Novartis Canada is pleased to announce that Health Canada has granted a Notice of Compliance (NOC) for KISQALI ® (ribociclib tablets) in combination with an aromatase inhibitor (AI) for the adjuvant treatment of adult patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) stage II-III early breast cancer (eBC) at high risk of recurrence. 2
Breast cancer is one of the most common cancers globally, 6 with HR+/HER2- being the most prevalent subtype, accounting for approximately 70% of cases. 7,8,9 Over 40% of HR+/HER2- breast cancer cases are diagnosed at stage II or III, with a high risk of recurrence for up to 20 years.8, 9 If cancer recurs, it is often metastatic which in most cases is considered incurable. 10,11 This progression significantly increases the burden on patients, caregivers, and healthcare systems, both financially and emotionally. 11,12 On average, 15 Canadian women will die from breast cancer every day. 13
"Over our years supporting younger patients, we've seen far too many with HR+ breast cancer become metastatic even while on maintenance endocrine therapy," said MJ DeCoteau, Founder and Executive Director, Rethink Breast Cancer. "Breast cancer is often more aggressive in younger patients, and they have higher rates of recurrence despite early treatment. So, we were thrilled to see that the positive results for KISQALI for early breast cancer are the same for patients of all ages, regardless of stage and nodal status. Our community desperately wants more effective tools to help improve their chances against this challenging disease that's turned their life plans upside-down. This Health Canada approval is an exciting step forward."
The Health Canada approval is based on the global Phase III NATALEE trial, which included a broad patient population with HR+/HER2- stage II and III eBC. At the final analysis, this clinical trial demonstrated a statistically significant and clinically meaningful reduction in the risk of disease recurrence with ribociclib plus AI compared to AI alone. Among patients with stage II and stage III eBC, ribociclib added to AI demonstrated a 25.1% relative reduction in the risk of an invasive disease-free survival (iDFS) event compared with AI alone, 1 with a well-tolerated safety profile seen across all subgroups in pivotal Phase III NATALEE trial. 2,4,14,15
"In the NATALEE trial, ribociclib demonstrated significant efficacy for a broad population of patients with early breast cancer," 2 said Dr. Stephen Chia, Medical Oncologist, BC Cancer and Steering Committee member of the NATALEE trial. "This approval provides a new and expanded treatment option for these patients to help reduce their risk of cancer returning. Patients deserve access to the most effective treatment options, and their individual needs should always be at the centre of shared decision making. In every situation, it's critical to have an open, balanced risk-benefit discussion, in order to make the appropriate treatment decision that's best suited for the patient to reduce the risk of their cancer returning."
"While the risk of cancer returning peaks in the first five years after diagnosis, more than half of recurrences occur after this period, and the majority are metastatic and incurable," 16,17 said Dr. Katarzyna Jerzak, Medical Oncologist, Sunnybrook Health Sciences Centre. "Ribociclib provides a new treatment option to help reduce the risk of recurrence and improve outcomes, particularly for patients at elevated risk. This approval expands our treatment arsenal with a targeted therapy that will have a meaningful impact on improving the care of patients diagnosed with early breast cancer in Canada."
"Novartis has been advancing innovative research and medical practice in breast cancer care for over 35 years, developing one of the most comprehensive pipelines in the field. Over 100,000 people with HR+/HER2- metastatic breast cancer have been treated with KISQALI globally, 18 and now we're focused on expanding its use to those with stage II or III HR+/HER2- early breast cancer to reduce risk of recurrence," said Mark Vineis, Country President, Novartis Canada. "We are actively committed to working with our health system partners to ensure timely access to KISQALI and supporting Canadians and healthcare professionals to improve health outcomes."
About early breast cancer (eBC)
Breast cancer is the most commonly diagnosed cancer among Canadian women, with approximately 70% of cases diagnosed in the early stages of the disease. 7,8,11 However, despite existing treatment options, people with stage II and III HR+/HER2- eBC remain at significant risk of recurrence. 11,12
The risk of recurrence is influenced by factors such as lymph node involvement, tumor size, age at diagnosis, and biomarkers. While patients without lymph node involvement typically have a lower risk, nearly 25% of those with HR+/HER2- eBC may experience recurrence within 20 years, 1 peaking after the first five years. 19 However, more than half of recurrences still happen after five years and more than 80% of these cases are metastatic and incurable. 20
About KISQALI ® (ribociclib tablets)
KISQALI was previously approved by Health Canada on March 2, 2018, for the treatment of patients with HR+/HER2- advanced or metastatic breast cancer. 20
KISQALI is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced precision may play a role in ensuring that cancer cells do not continue to replicate uncontrollably. 2
In eBC, KISQALI is the only CDK4/6 inhibitor recommended for both all node-positive disease and patients with no nodal involvement with high-risk disease characteristics. 20,21 The National Comprehensive Cancer Network (NCCN) guidelines recommend ribociclib (KISQALI) as a Category 1 preferred CDK4/6 inhibitor for breast cancer patients. 21 KISQALI, in combination with an AI, has the highest score (A) on the ESMO-Magnitude of Clinical Benefit Scale for the adjuvant treatment of adults with stage II and III HR+/HER2- eBC, at high risk of recurrence. 22
The most common Adverse Drug Reactions across the NATALEE study (>20% and exceeding the frequency for AI alone) were neutropenia (62.5% vs. 4.6%), infections (36.3% vs. 26.3%), nausea (23.3% vs.7.8%, headache (23.0% vs. 17.1%), fatigue (22.3% vs. 13.2%), leukopenia (22.3% vs. 3.6%), and abnormal liver function tests (22.3% vs. 7.6%). 2
Please see the Product Monograph for KISQALI, available at https://www.novartis.com/ca-en/kisqalimonograph.
About NATALEE
NATALEE is a global Phase III multi-centre, randomized, open-label trial to evaluate the efficacy and safety of KISQALI with an AI as an investigational adjuvant treatment versus AI alone in patients with stage II and III HR+/HER2- eBC. The adjuvant ET in both treatment arms was a non-steroidal aromatase inhibitor (NSAI; anastrozole or letrozole) and goserelin, if applicable. The primary endpoint of NATALEE was invasive disease-free survival (iDFS) as defined by the Standardized Definitions for Efficacy End Points (STEEP) criteria. A total of 5,101 adult patients with HR+/HER2- eBC across 20 countries were randomized in the trial. 13,23
About Novartis
Novartis is a focused innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide.
In Canada, Novartis Pharmaceuticals Canada Inc. employs approximately 600 people to serve the evolving needs of patients and the healthcare system and invests over $30 million in R&D yearly in the country. For more information visit www.novartis.ca.
SOURCE Novartis Pharmaceuticals Canada Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Toronto Star
10 hours ago
- Toronto Star
Doug Ford extends term of Ontario's top civil servant
Premier Doug Ford, right, and then-Trillium Health Partners Hospital CEO and President Michelle DiEmanuele show off the Moderna COVID-19 vaccine at Trillium Health Partners during the COVID-19 pandemic in Mississauga on Dec. 30, 2020. Nathan Denette THE CANADIAN PRES
Winnipeg Free Press
15 hours ago
- Winnipeg Free Press
Foreign medical residents fill critical positions at US hospitals, but are running into visa issues
Some hospitals in the U.S. are without essential staff because international doctors who were set to start their medical training this week were delayed by the Trump administration's travel and visa restrictions. It's unclear exactly how many foreign medical residents were unable to start their assignments, but six medical residents interviewed by The Associated Press say they've undergone years of training and work only to be stopped at the finish line by what is usually a procedural step. 'I don't want to give up,' said a permanent Canadian resident who matched to the University of Pittsburgh Medical Center Harrisburg but had her visa denied because she is a citizen of Afghanistan. She requested to remain anonymous for fear of reprisal. 'But the situation also seems so helpless.' Initially, the medical community was worried that hundreds of positions — many in hospitals in low-income or rural areas of the U.S. — could be affected. The pause on interviews for J-1 visas for approved work or study-related programs was lifted in mid-June. The national nonprofit that facilitates the residency match process said the visa situation is resolving, but it will take weeks to know with confidence how many medical residents have had the start of their careers derailed because they got their visa too late or were blocked by President Donald Trump's travel ban on 12 countries, according to people who coordinate the residents' training. Four foreign medical residents told the AP that U.S. embassies have been slow to open up interview slots — and some have not opened any. 'You lose out on the time you could have used to treat patients,' said one resident from Pakistan, who matched to an internal medicine program in Massachusetts and requested to remain anonymous for fear of reprisal. Thousands of foreign medical residents fill gaps in U.S. hospitals The U.S. is projected to face a physician shortage in the next 11 years, per the Association of American Medical Colleges, and foreign medical residents fill critical gaps in the health care system. More than 6,600 foreign-born international medical residents matched into U.S. programs in 2025 — the highest on record — and another 300 filled positions that were vacant after the match process was complete. Not all of those residents were affected by visa issues or the travel ban on foreign nationals from countries including Afghanistan, Haiti and Sudan. International medical graduates often take jobs in places where U.S. medical trainees tend not to go, said Donna Lamb, president of the National Resident Matching Program. 'It's not just that they're coming in and they want to work in big, flashy centers on the coast,' Lamb said. 'They're truly providing health care for all of America.' Foreign medical residents work in specialties that U.S. applicants aren't as eager to apply to. For example, international candidates make up almost 40% of residents in internal medicine, which specializes in the prevention and treatment of chronic conditions like diabetes and heart disease. 'The residents are the backbone of the entire hospital,' said Dr. Zaid Alrashid from Brookdale University Hospital and Medical Center in New York, which has medical residents from almost every continent. Most received their visas prior to the pause but a few were caught up in delays. Two residents from India who spoke on condition of anonymity have not been able to get an appointment at any U.S. embassies there despite the J-1 visa pause being lifted. Another resident from Egypt just secured a visa appointment for mid-August but is worried her program may not be willing to wait for her. She's already paid her security deposit for an apartment in Texas to live during her residency. 'I don't know when this situation will be resolved,' said the resident, who spoke on condition of anonymity, adding she hasn't been eating or sleeping well. Hospitals waiting for residents to arrive In California, leaders at two graduate medical education programs said they have a small number of residents caught up in J-1 visa delays. Both spoke on condition of anonymity due to concerns for the doctors who are still trying to get visas. A residency leader at one large health care system said two doctors in its 150-resident program are delayed, adding they could start late or defer to next year. A 135-person program at a California public health system told the AP that one resident has yet to arrive, though he was finally scheduled for a visa interview. 'We are not going to breathe easy until he's here in our hospital,' the second leader said. As of Wednesday, Lamb's matching program had received fewer than 20 requests to defer or cancel residency contracts. Worried about losing their spots if they defer, many foreign medical residents may keep trying to get to the U.S. and start their residencies late, said Dr. Sabesan Karuppiah, a past member of the American Medical Association's International Medical Graduates Governing Council and former director of a large residency program. Wednesdays Columnist Jen Zoratti looks at what's next in arts, life and pop culture. Some hospitals may struggle at this point to replace the residents who don't make it, leaving fewer people to care for the same number of patients, said Kimberly Pierce Burke, executive director of the Alliance of Independent Academic Medical Centers. Foreign medical trainees who've made it into the U.S. remain on edge about their situations, Karuppiah said. 'I can tell you the word on the street is: 'Do not leave the country,'' he said, adding that people are missing out on important events, seeing sick parents or even getting married. 'Everybody's scared to just leave, not knowing what's going to happen.' —- The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Calgary Herald
a day ago
- Calgary Herald
Mom who suffered stroke after giving birth emerges from 18-day coma
A Calgary mother of three who suffered a severe stroke after giving birth has come out of a coma, her husband said Thursday. Article content Iffat Shakti, 28, suffered a hemorrhagic stroke June 12, a week after the birth of daughter Julia Ameera, then experienced a second stroke and remained in a coma for the rest of the month. Article content Article content But three days ago, the woman opened her eyes, though remains unresponsive, said husband Marco Martel. Article content Article content Article content That condition is a sign of brain damage from the two strokes, said Martel, who's been at his wife's side at the Foothills Medical Centre daily. Article content 'That's what worries me the most – when the brain swelling goes down we'll know the extent of the damage to her brain,' he said. Article content Physicians, he said, have told him his wife still might not survive her ordeal and to 'prepare for the worst.' Article content But the man said he's placed his faith in a higher power, who's seems to want his wife to survive her ordeal, which was brought on by her high blood pressure. Article content But he's also been relying on the generosity of family, friends and strangers who have so far pledged about $19,500 in donations at a GoFundMe page set up to cover the family's expenses. Article content Article content 'When she comes out of the hospital, we know she'll have special needs like a bed and wheelchair,' said Martel. Article content His family will also need support as he's been unable to tend to their property rental business while he takes care of their new daughter, two young boys and spends time at the hospital, he said. Article content The auto body detailer says he's paying loans on three rental properties, and his absence makes it difficult to find renters to pay for them. Article content Shakti, he said, handled the financial end of the business, adding he's slowly learning that task. Article content 'I've got a lot on my plate,' he said. Article content 'I just want to bring her home but the best care she'll get is in the hospital.' Article content Shakti, who came to Canada from her native Bangladesh in 2018, was set to take her Canadian citizenship exam last month when she suffered her strokes. Article content
